Device for the transdermal administration of a rotigotine base consisting of a matrix polymer

Disclosed herein is a polymer matrix suitable for the transdermal administration of rotigotine [(-)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix polymer which is supersaturated with a rotigotine base, wherein the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 micrometer, and the matrix is free of solvents, crystallisation inhibitors and dispersants. The disclosure also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.